Persistent Uncontrolled Severe Asthma Despite Widespread Biologic Use: Care Gaps from the French FASE2-CPHG Real-World Study
The Journal of Allergy and Clinical Immunology: In Practice · 2026-11 · 14 (11) · 2625-2633
DOI: 10.1016/j.jaip.2026.08.010 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026-11. Verfasst von Laurent Portel und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre Hospitalier Robert Boulin, Libourne, France. Electronic address: laurent.portel@ch-libourne.fr. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents, Biological Products. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Biologic therapies have transformed the management of severe asthma, yet many patients in routine care remain symptomatic. Most real-world data originate from tertiary centers and may not reflect broader health care delivery. OBJECTIVE: To describe disease control, exacerbations, adherence, comorbidities, phenotypes, and care gaps in adults with severe asthma managed in French nonacademic hospitals in the biologic's era. METHODS: France Asthme Sévère-Collège des Pneumologues des Centres Hospitaliers Généraux (FASE2-CPHG) was a national, multicenter, cross-sectional study conducted between 2022 and 2023 in French nonacademic hospitals. Adults with Global Initiative for Asthma 2022 Step 5 asthma were consecutively included during routine care. Physicians completed electronic case report forms and patients completed questionnaires assessing asthma control (Asthma Control Test [ACT]), adherence (Girerd score), anxiety and depression (Hospital Anxiety and Depression Scale), and physical activity (Ricci-Gagnon questionnaire). Clinical characteristics, biomarkers, imaging, exacerbations, and treatments, including biologics, were recorded. RESULTS: Among 970 patients (mean age, 54.5 ± 15.8 years; 66.3% female), 71.2% were receiving biologic therapy. Despite these treatments, 59.8% had partially controlled or uncontrolled asthma according to the ACT questionnaire. Globally, 62.6% experienced at least 1 exacerbation in the previous year. The median annual exacerbation rate was 1 (interquartile range, 0-3). Only 31.6% of patients reported full adherence, whereas 88.7% were considered adherent by physicians. Anxiety and depressive symptoms were present in 45.6% and 24.6% of patients, respectively. Biologic therapy was prescribed in 71.2% of patients, with omalizumab used in most case (41.2%). The mean duration of the ongoing treatment with biologics was 2.9 years (±5.1 years). CONCLUSIONS: In routine nonacademic hospital practice, biologics are widely implemented, but a majority of patients remain uncontrolled. Major care gaps include unrecognized poor adherence; high psychological, metabolic, and ears, nose, and throat comorbidity burden; and incomplete optimization of inhaled therapy. Addressing these gaps may yield gains comparable to the introduction of new biologic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre Hospitalier Robert Boulin, Libourne, France. Electronic address: laurent.portel@ch-libourne.fr.
- Centre Hospitalier de La Cote Basque, Bayonne, France.
- CHPF du Taaone, Pirae, Polynésie française, France.
- Centre Hospitalier de Cannes, Cannes, France.
- Groupe Hospitalier Intercommunal Le Raincy Montfermeil, Montfermeil, France.
- Centre Hospitalier du Mans, Le Mans, France.
Zitieren
APA
Portel, L., Nocent-Ejnaini, C., Parrat, E., Verdoire, P., Maurer, C., Goupil, F., Texier, N., Hervy, S., Raherison-Semjen, C., Morel, H., & Humbert, M. (2026). Persistent Uncontrolled Severe Asthma Despite Widespread Biologic Use: Care Gaps from the French FASE2-CPHG Real-World Study. The Journal of Allergy and Clinical Immunology: In Practice, 14(11), 2625-2633. https://doi.org/10.1016/j.jaip.2026.08.010
Vancouver
Portel L, Nocent-Ejnaini C, Parrat E, Verdoire P, Maurer C, Goupil F, et al. Persistent Uncontrolled Severe Asthma Despite Widespread Biologic Use: Care Gaps from the French FASE2-CPHG Real-World Study. The Journal of Allergy and Clinical Immunology: In Practice. 2026;14(11):2625-2633. doi:10.1016/j.jaip.2026.08.010
BibTeX
@article{Portel2026,
author = {Portel, Laurent and Nocent-Ejnaini, C and Parrat, E and Verdoire, P and Maurer, C and Goupil, F and Texier, N and Hervy, S and Raherison-Semjen, C and Morel, H and Humbert, M},
title = {Persistent Uncontrolled Severe Asthma Despite Widespread Biologic Use: Care Gaps from the French FASE2-CPHG Real-World Study},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2026},
volume = {14},
number = {11},
pages = {2625--2633},
doi = {10.1016/j.jaip.2026.08.010}
}
EUVIMED